Disease · MONDO_0000726

idiopathic scoliosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. idiopathic scoliosis. Diseases, record MONDO_0000726. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000726

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: idiopathic scoliosis; Open Targets
Open Targets ID: MONDO_0000726; Open Targets
Disease Ontology: DOID:0060250; Disease Ontology
Highest stage of its drugs: Phase 2, for 3 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
KETAMINE HYDROCHLORIDE	CHEMBL1714	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MORPHINE HYDROCHLORIDE	CHEMBL556578	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
REMIFENTANIL HYDROCHLORIDE	CHEMBL1201120	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXTROSE	CHEMBL1222250	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116444	Drugs and targets
OPRM1	Mu-type opioid receptor	1	Mu opioid receptor agonist	Phase 2	https://conductscience.org/library/genes/4988	Drugs and targets
PLG	Plasminogen	1	Plasminogen inhibitor	Phase 1/2	https://conductscience.org/library/genes/5340	Drugs and targets
SCN4A	Sodium channel protein type 4 subunit alpha	1	Sodium channel protein type IV alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6329	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01813058	Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?	Phase 1/2	120	2019-02-20	Adolescent Idiopathic Scoliosis	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07581457	Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery	Not applicable	90		Scoliosis Idiopathic, Scoliosis; Adolescence	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02571491	Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery	Phase 2	48		Progressive Infantile Idiopathic Scoliosis	KETAMINE HYDROCHLORIDE, MORPHINE HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04336046	Ultrasound Guided Bilateral Erector Spinae Block as Analgesia for Adolescent Idiopathic Scoliosis Correction	Not applicable	40		Erector Spinae Block, Analgesia, Scoliosis Idiopathic	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tranexamic Acid vs Placebo: deaths from any cause	0 of 56	0 of 55	111	NCT01813058	Trial comparisons
Tranexamic Acid vs Placebo: serious adverse events	0 of 56	0 of 55	111	NCT01813058	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23371895	RESULT	1	PubMed
21364458	RESULT	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000726

GET https://conductscience.org/api/diseases/v1/MONDO_0000726/drugs

API reference For AI assistants